secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0001640334-23-001869
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria receives Nasdaq bid price deficiency notice; 180-day cure until April 15, 2024
--------------------------------------------------------------------------------

- Received Nasdaq notice on Oct 17, 2023 for failing to maintain $1.00 minimum bid price for continued listing on Nasdaq Capital Market.
- Has 180 calendar days (until April 15, 2024) to regain compliance by closing at $1.00+ for 10 consecutive business days.
- Shareholders approved a reverse stock split on Oct 10, 2023 as a potential cure; company states split remains last option.
- If not cured by April 15, may qualify for an additional 180-day compliance period if other listing standards are met.
- Stock continues trading under symbol LEXX; no immediate delisting effect, but no assurance of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423001869/0001640334-23-001869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423001869/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-23-001869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer